The estimated Net Worth of Robert G L Shorr is at least 188 千$ dollars as of 16 December 2015. Robert Shorr owns over 10,800 units of Brainstorm Cell Therapeutics stock worth over 7,952$ and over the last 19 years Robert sold BCLI stock worth over 180,480$.
Robert has made over 5 trades of the Brainstorm Cell Therapeutics stock since 2009, according to the Form 4 filled with the SEC. Most recently Robert sold 10,800 units of BCLI stock worth 29,268$ on 16 December 2015.
The largest trade Robert's ever made was selling 200,000 units of Brainstorm Cell Therapeutics stock on 4 October 2011 worth over 62,000$. On average, Robert trades about 25,388 units every 132 days since 2005. As of 16 December 2015 Robert still owns at least 28,399 units of Brainstorm Cell Therapeutics stock.
You can see the complete history of Robert Shorr stock trades at the bottom of the page.
Robert's mailing address filed with the SEC is 28 BROOKFALL ROAD, , EDISON,, NJ, 08817.
Over the last 21 years, insiders at Brainstorm Cell Therapeutics have traded over 1,899,994$ worth of Brainstorm Cell Therapeutics stock and bought 1,713,254 units worth 1,535,874$ . The most active insiders traders include Corp. Accbt、Mike Frankenberger、International Holdings Ltd..... On average, Brainstorm Cell Therapeutics executives and independent directors trade stock every 145 days with the average trade being worth of 206,459$. The most recent stock trade was executed by Ibrahim B. Dagher on 19 July 2024, trading 63,000 units of BCLI stock currently worth 22,050$.
brainstorm cell therapeutics inc. (nasdaq:bcli), is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative disorders such as als (lou gehrig's disease), multiple sclerosis (ms) and parkinson’s disease (pd). these diseases have limited treatment options and as such represent unmet medical needs. nurown™ is brainstorm’s proprietary process for the propagation and differentiation of adult, autologous mesenchymal stem cells (msc) into neurotrophic factor (ntf)-secreting cells, and the transplantation of these specialized cells at or near the affected tissue site. our platform technology essentially converts mscs into living drug delivery system for ntfs. we have obtained proof-of-concept in a variety of animal models of neurodegenerative diseases, including parkinson's, huntington's, als, ms, and peripheral nerve injury. we have completed two single-arm clinical trials in als patients, conducted in israel, which have demonstr
Brainstorm Cell Therapeutics executives and other stock owners filed with the SEC include: